TLDR:
- Amsterdam-based NLC Health Ventures and Alphabet’s healthtech company Verily have launched a new biotech startup called Exolvo Biosciences.
- Exolvo aims to improve drug delivery technology for biologic drugs, making treatments more accessible and less invasive.
Amsterdam-based NLC Health Ventures, in collaboration with Verily (an Alphabet Inc. company), has announced the launch of Exolvo Biosciences, a biotech startup focusing on biologic drug delivery technology. This new venture aims to address the challenges associated with the oral delivery of large and complex molecules, providing a more patient-friendly and efficient treatment experience. Exolvo’s technology, which includes flexible capsule sizes and modular designs, has the potential to revolutionize how biologic drugs are administered, ultimately improving patient outcomes and reducing healthcare costs.
The co-founder and CEO of Exolvo, Brian Longstreet, emphasizes the need for innovative solutions in drug delivery to make treatments more accessible and less invasive for individuals living with chronic conditions. The company is actively engaged in advancing its technology and aims to collaborate with key pharmaceutical and biotech partners to bring about meaningful change in the healthcare industry.
NLC Health Ventures, recognized as the most active health technology investor in Europe, plays a pivotal role in supporting and scaling transformative health innovations. With a focus on providing quality care to patients, NLC invests in startups and ventures that align with its mission. The NLC Health Impact Fund, the organization’s largest fund to date, offers financial support to startups at various stages of growth, contributing to the development of impactful and sustainable health solutions.
